Command Palette

Search for a command to run...

PPLPHARMA

192.132.72 (1.44%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly in the latest quarter (202503) to ₹2754.07 crore from ₹2204.22 crore, showing strong growth.
  • Operating margin improved dramatically to 7.79% in Q3 2025, a recovery from previous lows, indicating better cost management.
  • Net profit rebounded to ₹153.5 crore in Q3 2025, compared to a minimal profit of ₹3.68 crore in Q2 2024.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendSep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25
Revenue
1,911.381,958.572,552.361,951.142,241.752,204.222,754.071,933.71
Expenses
1,940.121,982.402,332.782,038.162,2002,166.602,539.522,110.44
Operating Profit
-28.74-23.83219.58-87.0241.7537.62214.55-176.73
Other Income
49.1961.5126.3819.5461.1112.1342.0358.40
Interest
109.87105.88114.22106.96107.64103.31103.6886.15
Depreciation
184.51186.32196.13184.55192.22196.81242.76197.28
Profit Before Tax
39.5619.36227.48-45.08120.1266.80272.80-79.02
Tax
34.549.25126.2143.5697.5363.12119.302.68
Net Profit
5.0210.11101.27-88.6422.593.68153.50-81.70
EPS in Rs
0.040.080.77-0.670.170.031.16-0.62